ETFOther ETFsDirectGrowthVery High

Nippon India Nifty Pharma ETF

Q: What is the NAV of Nippon India Nifty Pharma ETF?

As of 20 Aug 2026, the NAV of Nippon India Nifty Pharma ETF is ₹27.17 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

Q: What returns has Nippon India Nifty Pharma ETF delivered?

Nippon India Nifty Pharma ETF has returned +20.67% over 1 year, +20.49% per year over 3 years, +14.58% per year over 5 years and +13.18% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

Q: What is the expense ratio of Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF charges an expense ratio of 0.24% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

Q: What are the top holdings of Nippon India Nifty Pharma ETF?

Its largest holdings are Sun Pharmaceutical Industries (21.3%), Divi's Laboratories (10.3%), Cipla (8.4%), Torrent Pharmaceuticals (7.6%) and Laurus Labs (7.1%). Holdings are disclosed monthly and change over time.

Q: How risky is Nippon India Nifty Pharma ETF?

It is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 15.1% and its worst peak-to-trough fall in our sample was -21.0%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

Q: What does the Sharpe ratio of 0.93 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Nippon India Nifty Pharma ETF's 0.93 means it has rewarded its volatility with excess return. Higher is better.

Q: What is the benchmark of Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF is benchmarked against the Nifty Pharma TRI. Its alpha and beta on this page are measured against that index.

Q: Who manages Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF is managed by Himanshu Mange and Jitendra Tolani at Nippon India.

Q: How is Nippon India Nifty Pharma ETF taxed?

Nippon India Nifty Pharma ETF is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.

Nippon India Mutual Fund

NAV

₹27.17

+0.39% 1D

as of 20 Aug 2026

Compare SIP calculator

Performance

+20.09%CAGR

52-week rangePrev NAV ₹27.06

Latest ₹27.17

Low ₹21.9894th percentile of its 52-week rangeHigh ₹27.52

Scorecard

★★★★★5/5 vs 21 of 38 Other ETFs peers

Performance 60%
Risk 15%
Cost 10%
Downside 15%

How this is computed

Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. The stars weight the same ground 60/15/10/15 (performance/risk/cost/downside) across every fund in the peer group. Ranked within Other ETFs (same plan and option). 21 of the 38 Other ETFs funds in this cohort carry the full record the stars need, so they are the ones ranked against.

PerformanceStrong

3Y CAGR +20.49% · ranks 6 of 38 Other ETFs funds

RiskModerate

Volatility 15.1% vs 16.2% category avg

CostLow

0.2% expense vs 0.4% category avg

ConsistencyHigh

100% of rolling 3Y windows were positive

Strengths & concerns

Generated from this fund's own numbers against its sub-category — each point names the figure behind it.

Strengths

Ahead of the Other ETFs average on 1M/3M/6M/1Y — 1Y by 6.89pp
3-year return (+20.49%) beats the Other ETFs average (+14.72%)
5-year return (+14.58%) beats the Other ETFs average (+11.57%)
Ranks #5 of 38 on 1-year return in its Other ETFs cohort
Stronger risk-adjusted returns — Sharpe 0.93 vs 0.32 Other ETFs average

Concerns

No significant concerns identified.

Key Metrics

Annual fee charged by the fund, already deducted from NAV

Category 0.37%

Portfolio-weighted harmonic mean P/E across the fund's equity holdings

Category 20.26

Excess return per unit of total volatility (rf = 6.5%)

0.93

Category 0.32▲0.61

Scheme Info

Definitions

Plan

Direct · Growth

Period before units can be redeemed — 3 years for ELSS, none for most open-ended funds

Exit Load

Statutory levy on every mutual-fund purchase since 1 Jul 2020 (SEBI / Govt of India) — the same for every scheme

0.005%

SIP Inv.

Smallest recurring SIP instalment the scheme accepts

Smallest one-time (lumpsum) investment the scheme accepts

Benchmark

Start of our NAV history for this plan. Direct plans begin 1 Jan 2013, so this is the plan's inception — not necessarily the scheme's original launch date.

06 Jul 2021

Period returns (<1Y, absolute — not annualized)

Definitions

Absolute return over the last 1 month (not annualized)

+3.07%

Absolute return over the last 3 months (not annualized)

+6.62%

Absolute return over the last 6 months (not annualized)

+17.91%

Absolute return since 1 Jan of this year (not annualized)

+17.20%

Annualized returns (≥1Y — CAGR)

Definitions

1-year point-to-point return, annualized (CAGR)

+20.67%

3-year annualized return (CAGR)

+20.49%

5-year annualized return (CAGR)

+14.58%

10-year annualized return (CAGR)

—

Annualized return (CAGR) since the fund's inception

+13.18%

Advanced metrics — risk and benchmark ratios

Risk (trailing 3Y)

Definitions

Annualized standard deviation of daily returns

15.10%

Excess return per unit of total volatility (rf = 6.5%)

0.93

Excess return per unit of downside deviation — upside swings aren't penalized (rf = 6.5%)

1.34

Largest peak-to-trough decline over full history

-20.98%

Benchmark ratios (vs Nifty 500 · 36 monthly returns)

Definitions

Jensen's alpha (annualized): return above what CAPM predicts for the fund's beta vs Nifty 500

10.21%

Sensitivity to Nifty 500 moves; 1 = moves with the index

0.67

How much of the fund's movement Nifty 500 explains

41.1%

Excess return per unit of beta (market risk)

21.55

Active return over the benchmark per unit of tracking error

0.71

Annualized std dev of fund-minus-benchmark returns

13.27%

Fund's share of benchmark gains in up months (100 = matches index)

109.1%

Fund's share of benchmark losses in down months (lower is better)

60.3%

Computed vs the Nifty 500 price index — the closest match to this fund's mandate. Needs ~3 years of history; a low R² means the fund tracks the index loosely.

Fund vs category average (Other ETFs)

Period	Fund	Category avg.	Diff
1M abs	+3.07%	+2.27%	+0.80%
3M abs	+6.62%	+1.95%	+4.67%
6M abs	+17.91%	-0.19%	+18.10%
1Y CAGR	+20.67%	+13.78%	+6.89%
3Y CAGR	+20.49%	+14.72%	+5.77%
5Y CAGR	+14.58%	+11.57%	+3.01%

Category average across peers in Other ETFs (up to 38 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).

Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.

Category rank

Vs 38 peers in Other ETFs

1Y return

+20.67%

Beats 87.9% · rank #5

3Y return

+20.49%

Beats 75% · rank #6

5Y return

+14.58%

Beats 72.2% · rank #6

Sharpe

0.93

Beats 86.2% · rank #5

Sortino

1.34

Beats 86.2% · rank #5

Rolling returns

Return for every possible 1Y holding period, not just today’s

This fundNifty 500

Average

+16.5%

Median

+13.3%

Best

+58.4%

Worst

-13.2%

Positive periods

70.0%

50 overlapping 1Y windows, sampled monthly across the fund’s history.

Backtest this fund

What a SIP or one-time investment would have grown to over this fund’s real NAV history.

Monthly investment (₹)

Period

Invested

₹6.00L

Current value

₹9.57L

Absolute

+59.57%

XIRR

+19.35%

Value vs. invested

60 monthly installments of ₹10,000 into Nippon India Nifty Pharma ETF, valued at the latest NAV. XIRR annualizes for each installment’s timing.

Calendar-year returns

What the fund actually returned in each year, not the smoothed average.

Year	Fund	Nifty 500	Diff
2026part	+16.73%	-1.50%	+18.23%
2025	-2.46%	+6.69%	-9.15%
2024	+39.59%	+15.16%	+24.43%
2023	+34.44%	+25.76%	+8.68%
2022	-10.86%	+3.02%	-13.88%
2021part	-1.02%	—	—

January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.

History points

1,266

Expense ratio

AUM

Portfolio turnover

Exit load

P/E ratio

P/B ratio

Avg market cap

Taxation

Taxed as equity

This is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.

Short-term (STCG)

20%

Held under 1 year

Flat, on the whole gain

Long-term (LTCG)

12.5%

Held 1 year or more

On gains above ₹1.25 L per financial year

Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.

Peer comparison · Other ETFs

Compare all


Nippon India Nifty Pharma ETFThis fund Nippon India	★★★★★	+20.67%	+20.49%	+14.58%	39.81	0.24%	₹1,458Cr
Nippon India Silver ETF Nippon India	★★★★☆	+110.79%	+47.87%	—	—	0.58%	₹31,737Cr
CPSE ETF Nippon India	★★★★☆	+3.32%	+25.71%	+30.21%	13.52	0.08%	₹21,191Cr
Nippon India Nifty Auto ETF Nippon India	★★★★☆	+15.99%	+24.65%	—	14.75	0.22%	₹421.46Cr
Nippon India ETF Nifty PSU Bank BeES Nippon India	★★★☆☆	+21.56%	+23.40%	+31.44%	7.76	0.51%	₹4,041Cr
Nippon India ETF Hang Seng BeES Nippon India	★★☆☆☆	+14.02%	+21.07%	+8.45%	—	0.96%	₹1,058Cr

Market-cap allocation · AMFI bands, Jul 2026

Equity holdings by company size — 100% of the equity sleeve priced.

Large cap50.6%
Mid cap44.7%
Small cap4.7%

🚩Holdings under NSE surveillance (ASM)

1 holding — 1.63% of the portfolio — sit in stocks NSE currently lists under its Additional Surveillance Measure. ASM is an exchange response to unusual price or volume activity (higher margins, and trade-for-trade settlement at stage II), not a view on the company or on this fund.

Wockhardt LimitedLong-term · Stage I1.63%

Source: NSE ASM list, matched to holdings by company name — a holding whose name differs from NSE's spelling may not be matched. BSE's separate list is not covered.

Worst falls, and the wait to get back

How far this fund has dropped from a high, and how long it took to reclaim it.

-21.0%04 Oct 2021 → 13 Mar 2023
Fell over 17 months, back to the old high on 27 Jul 2023 — 4 months under water after the low.
-16.6%09 Oct 2024 → 28 Feb 2025
Fell over 5 months, back to the old high on 06 May 2026 — 14 months under water after the low.
-6.6%09 Aug 2023 → 26 Oct 2023
Fell over 3 months, back to the old high on 17 Nov 2023 — 22 days under water after the low.

Measured on this fund’s own NAV history, peak to trough to the day it regained the peak. Falls shallower than 5% are left out. A recovery date is when the NAV got back, not when any particular investor did — that depends on when they bought.

Fund size over time

Quarterly average AUM · AMFI

₹1,458Cr

April - June 2026

+39%

since January - March 2026

At or near its largest, ₹1,458Cr in April - June 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.

Nippon India in the news

Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.

Run SIP calculator Add to compare

Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.

About Index funds & ETFs

Index funds and ETFs simply track a benchmark such as the Nifty 50 rather than trying to beat it. They charge far lower fees than active funds, and their return is the index's return minus that small cost.

Frequently asked questions

What is the NAV of Nippon India Nifty Pharma ETF?

As of 20 Aug 2026, the NAV of Nippon India Nifty Pharma ETF is ₹27.17 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.

What returns has Nippon India Nifty Pharma ETF delivered?

Nippon India Nifty Pharma ETF has returned +20.67% over 1 year, +20.49% per year over 3 years, +14.58% per year over 5 years and +13.18% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.

What is the expense ratio of Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF charges an expense ratio of 0.24% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.

What are the top holdings of Nippon India Nifty Pharma ETF?

Its largest holdings are Sun Pharmaceutical Industries (21.3%), Divi's Laboratories (10.3%), Cipla (8.4%), Torrent Pharmaceuticals (7.6%) and Laurus Labs (7.1%). Holdings are disclosed monthly and change over time.

How risky is Nippon India Nifty Pharma ETF?

It is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 15.1% and its worst peak-to-trough fall in our sample was -21.0%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.

What does the Sharpe ratio of 0.93 mean?

The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Nippon India Nifty Pharma ETF's 0.93 means it has rewarded its volatility with excess return. Higher is better.

What is the benchmark of Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF is benchmarked against the Nifty Pharma TRI. Its alpha and beta on this page are measured against that index.

Who manages Nippon India Nifty Pharma ETF?

Nippon India Nifty Pharma ETF is managed by Himanshu Mange and Jitendra Tolani at Nippon India.

How is Nippon India Nifty Pharma ETF taxed?

Nippon India Nifty Pharma ETF is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.